Coya Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Coya Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has a cash flow conversion efficiency ratio of -0.316x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.67 Billion) by net assets ($43.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Coya Therapeutics, Inc. Common Stock (2020–2025)
Cash flow conversion efficiency of Coya Therapeutics, Inc. Common Stock from 2020 to 2025. This chart illustrates how Coya Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Coya Therapeutics, Inc. Common Stock for real-time trading data and today's change.
Coya Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Coya Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Coya Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see COYA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Act Co Ltd
KQ:138360
|
-0.024x |
|
Talga Group Ltd
AU:TLG
|
-0.155x |
|
Country View Bhd
KLSE:5049
|
0.177x |
|
Eco World International Bhd
KLSE:5283
|
-0.054x |
|
Altenergy Acquisition Corp
NASDAQ:AEAE
|
0.023x |
|
Technology & Telecommunication
NASDAQ:TETE
|
0.010x |
|
kenturn Nano Tec Co Ltd
TWO:4561
|
-0.005x |
|
Zhulian Corporation Bhd
KLSE:5131
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Coya Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Coya Therapeutics, Inc. Common Stock from 2020 to 2025. Review Coya Therapeutics, Inc. Common Stock free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $43.03 Million | $-10.74 Million | -0.250x | +3.99% |
| 2024-12-31 | $39.58 Million | $-10.29 Million | -0.260x | +17.20% |
| 2023-12-31 | $35.64 Million | $-11.19 Million | -0.314x | -136.40% |
| 2022-12-31 | $-8.39 Million | $-7.24 Million | 0.862x | +180.51% |
| 2021-12-31 | $3.64 Million | $-3.90 Million | -1.071x | -2172.96% |
| 2020-12-31 | $8.30 Million | $-391.27K | -0.047x | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more